Absci Corporation is classed by the SEC under Services-Commercial Physical & Biological Research (industry code 8731), based in Vancouver, WA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $5 million and a loss of $115 million (its filed statements).
Pre-revenue companyServices-Commercial Physical & Biological ResearchVancouver, WAfilings since 20168 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 8731), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 3.8 out of ten, 8 of 9 metrics filed and 1 estimated: past 3.2 out of ten, present 4.1 out of ten, future 3.8 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 7.9 out of ten. No warning events in its filings since 2017. 79th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 2.4 out of ten. -7.4% a year over 6 filed years; profitable in 0 of 6. 24th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 1.3 out of ten. CrossAssetData estimate 1.3/10, confidence 35 of 100 (one part). 13th percentile among 12 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 4.7 out of ten. ROE -61%: lost 61¢ per shareholder dollar. Leverage 12%: owes 12¢ per asset dollar. 46th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 1.5 out of ten. bottom 15% of 12 in its family; net margin -4113.7%. 15th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 5.0 out of ten. bottom 50% of 8 in its family for leadership; chief executive since 2021. 50th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 4.7 out of ten. bottom 47% of 12 in its family for room to expand. 47th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 3.8 out of ten. bottom 38% of 12 in its family for growth drivers. 38th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 2.6 out of ten. bottom 26% of 11 in its family for expectations against reality. 26th percentile among 11 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-24 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-11 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-11 (on EDGAR). Newest filing: Form 4, 2026-09-01. Filings on record since 2016. Read from EDGAR 2026-10-12.
Who runs it
Mcclain, Sean (Chief Executive Officer); Jonasson, Zachariah (CFO / CBO); Busch, Andreas (Chief Innovation Officer); Walker, Shelby J. (Chief Legal Officer); Somaratne, Ransi Mudalinayake (CMO, Head of R&D); Bedrick, Todd (SVP, CAO); Szela, Mary T (director); Mcginnis, Karen K (director); Pangalos, Menelas N (director); Rabinovitsj, Daniel A (director); and 2 more. 12 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.